Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11859012 Heterodimeric antibodies that bind CD3 and GPC3

Patent 11859012 was granted and assigned to Xencor on January, 2024 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
0
Current Assignee
Xencor
Xencor
0
Date Filed
March 10, 2022
0
Date of Patent
January 2, 2024
0
Patent Applicant
Xencor
Xencor
0
Patent Application Number
17692045
0
Patent Citations
‌
US Patent 7276497 Cytotoxic agents comprising new maytansinoids
0
‌
US Patent 6884869 Pentapeptide compounds and uses related thereto
0
‌
US Patent 6989452 Disulfide prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7087600 Peptidyl prodrugs and linkers and stabilizers useful therefor
0
‌
US Patent 7112324 CD 19×CD3 specific polypeptides and uses thereof
0
‌
US Patent 7129261 Cytotoxic agents
0
‌
US Patent 8409568 Mutant antibody Fc domains and fusion proteins thereof
0
‌
US Patent 8592562 Method for making antibody Fc-heterodimeric molecules using electrostatic steering effects
0
‌
US Patent 8637641 Antibodies with modified isoelectric points
0
‌
US Patent 8946387 FcγRIIB specific antibodies and methods of use thereof
0
•••
Patent Inventor Names
Matthew J. Bernett
0
Nargess Hassanzadeh-Kiabi
0
Katrina Bykova
0
Rajat Varma
0
Alex Nisthal
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
11859012
0
Patent Primary Examiner
‌
Adam Weidner
0
CPC Code
‌
A61P 35/00
0
‌
C07K 16/2809
0
‌
C07K 16/468
0

Find more entities like US Patent 11859012 Heterodimeric antibodies that bind CD3 and GPC3

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo
By using this site, you agree to our Terms of Service.